Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Despite enormous progress in understanding COVID-19, there is little evidence that a solution, therapeutic or preventive, is close to being achieved. Repurposing of well known, widely available drugs represent an attractive approach to speed up availability of active treatments. Such substances as i.e. hydroxychloroquine and others, are already under investigation and in widespread off label use. For many reasons Methylene blue (MB), the oldest synthetic substance in medicine (1876 synthesized by BASF) is such a promising candidate for an active treatment against SARS-CoV-2 infected people and for COVID-19 patients.
Description: As primary outcome we will measure the viral load kinetics in the enrolled patients. This means the viral load (expressed as cycled of replication with the PCR method and the number of RNA copies) at baseline and at each scheduled timepoint of the study
Measure: to compare the viral load kinetics in the enrolled patients with a SARS-CoV-2 positive nasopharyngeal swab demonstrating a reduction of the area under the curve day 0- day 21 of at least 25% Time: day 0 - day 21Description: We report the number of patients (expressed as percentage) with negative oro-pharyngeal swab at the scheduled time-points
Measure: To calculate the percentage of patients clearing SARS-CoV-2 by 3, 6, 9, 12, 15 and 21 days after diagnosis Time: 3, 6, 9, 12, 15 and 21 days after diagnosisDescription: We calculate the number of patients (expressed as percentage) that have a decreased viral load (expressed as RNA copies) greater than 2 log by day three
Measure: To calculate the percentage of patients having a reduction of viral load of > 2 log by day 3 Time: day 3Description: We calculate the number of patients (expressed as percentage) that need hospitalization due to COVID-19, within the timeframe of the study
Measure: To calculate the percentage of patients having a poor outcome as measured by the need of hospitalization for COVID-19 Time: 3, 6, 9, 12, 15, 21, 28 and 84 days after diagnosisDescription: We calculate the number of patients (expressed as percentage) still alive at day 28 and 84 of samples collection
Measure: To calculate the percentage of patients alive Time: at 28-days and 84-daysDescription: Safety and tolerability of the administered drug are registered as "adverse events", which are all symptoms related or supposed to be related to the drug that appeared after the drug intake and were NOT present at baseline or before Adverse events are expressed as present (1) or absent (0), in the dedicated data sheet which will be collected at each scheduled visit
Measure: Safety and tolerability of the administered drug are registered as "adverse events", which are all symptoms related or supposed to be related to the drug that appeared after the drug intake and were NOT present at baseline or before Time: 3, 6, 9, 12, 15, 21, 28 and 84 days after diagnosisDescription: We calculate the number of pills (expressed as absolute number) taken by each enrolled patient during the study
Measure: To measure the compliance by calculating the number of capsules taken by the patient and the overall number of patients who complete the treatment Time: 3, 6, 9, 12, 15 and 21 days after diagnosisAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports